Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

Abstract Background Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3i naïve. The response rates to sequentia...

Full description

Bibliographic Details

Published in:	Journal of Hematology & Oncology
Main Authors:	Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Format:	Article
Language:	English
Published:	BMC 2020-10-01
Subjects:	FLT3 mutations Sequential FLT3 inhibitors Midostaurin Sorafenib Quizartinib Gilteritinib
Online Access:	http://link.springer.com/article/10.1186/s13045-020-00964-5